Riley Hospital for Children

Indiana University

Indiana University
705 Riley Hospital Dr
Indianapolis, IN 46202
United States
Call 866-230-8486 Email this location

Riley Hospital for Children is one of twenty-five Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Principal Investigator, Linda DiMeglio, MD, the TrialNet team at the Riley's is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Our Team

Principal Investigators 
After graduating from Harvard University with honors, Dr. DiMeglio obtained her MD from the University of Pennsylvania in Philadelphia, PA and performed her residency in Pediatrics at Children’s Memorial Hospital (Northwestern University) in Chicago, IL. She completed her fellowship in Pediatric Endocrinology and received her Master’s in Public Health from Indiana University-Purdue University, Indianapolis. Since her fellowship, Dr. DiMeglio has been working in clinical research with a focus on Type 1 diabetes prevention and treatments, including new technologies and therapies for metabolic bone disease. She currently directs Riley Hospital’s participation in a number of type 1 diabetes research networks and supervises a research staff of 5 nurses and three technicians. She also collaborates on a variety of other translational and clinical research projects. She is an active clinician, seeing patients with diabetes and endocrine disorders in clinics, and she teaches medical students, residents, housestaff, and fellows.
Research interests include different pathophysiologic processes affecting beta cell function in Type 1 and Type 2 Diabetes; clinical interests include pediatric endocrinology and diabetes. I am originally from the Southeast, but have enjoyed living in the Midwest with my husband and two sons, and becoming a part of the Riley community.
The long-range goal of the Evans-Molina lab is to define the pathways that govern beta cell function in states of health in order to understand how these regulatory circuits are impaired in the pathologic state of Type 2 diabetes mellitus. The major focus of the lab is to characterize changes in expression and activity of the sarco-endoplasmic reticulum Ca2+ ATPase or SERCA pump in the diabetic beta cell and to identify the downstream effects of SERCA dysregulation on ER calcium homeostasis, insulin production and secretion, and beta cell survival.
Heba Ismail is an Assistant Professor of Pediatrics in the Department of Pediatrics, Division of Endocrinology and Diabetology at Riley Hospital for Children. Amongst her many research interests, a large interest of hers is the work that is being done with Type 1 Diabetes TrialNet. Her main research focus is on understanding the pathogenesis and natural progression to Type 1 Diabetes. She has several publications in that area.
Research Coordinators 

Regional Affiliates

Ann Arbor

University of Michigan Health System
1500 E. Medical Center Dr, Ann Arbor, MI 48109


Ann & Robert H. Lurie Childrens Hospital of Chicago
225 E Chicago, Chicago, IL 60611


St. Johns Hospital & Medical Center
22201 Moross Road, SCPB II, Suite 270, Detroit, MI 48236


Henry Ford Medical Center
3031 West Grand Blvd, Detroit, MI 48202


Childrens Hospital of Michigan
3901 Beaubien Blvd, Detroit, MI 48201

Fort Wayne

Lutheran Childrens Hospital
7950 W. Jefferson Blvd, suite 210, Fort Wayne, IN 46804

Grand Rapids

DeVos Childrens Hospital at Spectrum Health Hospitals
15 Michigan Street NE, Suite 701, Grand Rapids, MI 49503


Presence Saint Joseph Medical Center
333 N. Madison St., Joliet, IL 60435


Western Michigan University School of Medicine
1000 Oakland Drive, Kalamazoo, MI 49008


University of Kentucky
1101 Veterans Drive 111-C, Lexington, KY 40502


University of Illinois College of Medicine at Peoria
530 NE Glen Oak Ave, Peoria, IL 61637


Springfield Clinic
1130 South 6th St. Ste. 100, Springfield, IL 62703


The University of Toledo
2142 North Cove Blvd., Conrad Jobst Tower, Suite 980, Toledo, OH 43606

Research Studies

Risk Screening

Pathway to Prevention

If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.


Prevention Study

Abatacept - Closed to Enrollment - Study Ongoing

TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.


Teplizumab (Anti-CD3)

We tested the drug teplizumab to see if it could delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.


Hydroxychloroquine (HCQ)

We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.



Long-Term Investigative Follow-Up in TrialNet (LIFT)

Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.